Marc Tessier-Lavigne, Director at REGENERON PHARMACEUTICALS, INC. (REGN), sold 29,000 shares at $564.45 ($16.4M) on 2020-05-06, disclosed to the SEC on 2020-05-08.
Open-market sale of $16.4M REGN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $562.65 | 1,025 | $577K | 3.5% |
| 2 | $562.65 | 1,025 | $577K | 3.5% |
| 3 | $563.45 | 6,375 | $3.6M | 22.0% |
| 4 | $563.45 | 6,375 | $3.6M | 22.0% |
| 5 | $564.45 | 6,600 | $3.7M | 22.8% |
| 6 | $564.45 | 6,600 |
| $3.7M |
| 22.8% |
| 7 | $565.35 | 900 | $509K | 3.1% |
| 8 | $566.01 | 100 | $57K | 0.3% |
| Total | $563.92 avg | 29,000 | $16.4M | 100% |
| Filing → |
| REGN | SELL | 2022-10-03 | $10.2M | — | Filing → |
| DNLI | SELL | 2022-09-30 | $1.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |